Mark Huffman, MD
Ophthalmology · London, KYNPI 1821085457
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 44.8% of the total. Reporting peaked in 2024 at $5,349 and has fallen 82.9% since, to $915 in 2025. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $73.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$5K
- Ivantis, Inc$1K
- Carl Zeiss Meditec, Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Glaukos Corporation$525
- Alcon$512
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,0008%
- Speaking & faculty fees$3,80631%
- Travel & lodging$2,18318%
- Food & beverage$5,14942%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 24 | $5,479 |
| Ivantis, Inc | 11 | $1,320 |
| Carl Zeiss Meditec, Inc. | 1 | $1,277 |
| Johnson & Johnson Surgical Vision, Inc. | 21 | $1,220 |
| Glaukos Corporation | 12 | $525 |
| Alcon | 20 | $512 |
| AbbVie(2 entities) | 13 | $406 |
| Sun Pharmaceutical Industries Inc. | 16 | $344 |
| Aerie Pharmaceuticals, Inc. | 11 | $282 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $139 |
| Biotissue Holdings Inc. | 3 | $112 |
| Ocular Therapeutix, Inc. | 6 | $101 |
| Leica Microsystems Inc. | 1 | $82 |
| Amgen | 4 | $75 |
| Kala Pharmaceuticals, Inc. | 3 | $65 |
| Bausch & Lomb Americas Inc. | 3 | $64 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $57 |
| Rayner Intraocular Lenses Limited | 2 | $35 |
| Novartis | 2 | $31 |
| Rxsight Inc | 1 | $26 |
| Beaver-visitec International, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$5,400
- IOLMaster 700$3,780
- CLARUS$2,700
- VisuMax$2,700
- QUATERA 700$2,299
- Hydrus Microstent$1,132
- VERACITY SURGICAL$1,080
- Tecnis IOL$260
- Ophthalmic Surgical Adjuncts$243
- Clareon$226
- Tecnis Simplicity$149
- DURYSTA$148
- TECNIS Presbyopia-Correcting IOLs$124
- CEQUA$114
- LUMERA 700$112
- Rhopressa$111
- Rocklatan$111
How this compares
$12,227 in reported general payments places this provider in the 90th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 36 | $56,247 |
| RestasisCyclosporine | 40 | $40,367 |
| LumiganBimatoprost | 76 | $34,200 |
| Prednisolone Acetate | 711 | $18,643 |
| MoxifloxacinMoxifloxacin Hcl | 550 | $14,100 |
| Cyclosporine | 17 | $11,649 |
| RhopressaNetarsudil Mesylate | 19 | $9,528 |
| Ketorolac Tromethamine | 599 | $8,360 |
| RocklatanNetarsudil Mesylat/Latanoprost | 23 | $8,205 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $6,234 |
| VyzultaLatanoprostene Bunod | 16 | $6,191 |
| Alphagan PBrimonidine Tartrate | 16 | $6,041 |
| Travoprost | 24 | $3,614 |
| Latanoprost | 357 | $3,562 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $3,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $406 | $83,728144 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $64 | $62,43852 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $282 | $17,73342 claims |
| AlconSimbrinza | $512 | $6,23432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in London
- James HuffmanLondon$6K
- Rebekah HuffmanLondon$4K
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.